Clinical Trial Update: Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial ASPEN-03 evaluating Evorpacept (ALX148) in combination with pembrolizumab for advanced head and neck squamous cell carcinoma is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Evorpacept (ALX148)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: ALX Oncology Inc. | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING